News Formal

Our biggest healthcare company says it isn’t scared of Ozempic

  • 📰 smh
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 80%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.

CSL boss Paul McKenzie is confident that weight-loss drugs such as Ozempic are no threat to the company’s success as the biotech giant champions growth opportunities after a week of heightened investor scrutiny.

CSL chief executive Paul McKenzie is confident the company can deliver double-digit annual earnings growth over the medium term.Analysts immediately began running the ruler over the impact that drugs such as Ozempic could have on CSL Vifor, the Swiss pharma firm that cost CSL more than $16 billion and is focused on kidney disease treatments. “We think this could be a potential negative catalyst on CSL,” Morgan Stanley analysts said last week.

“There is not a big correlation between obesity reduction and the disease states that we work in,” McKenzie said.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 6. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

CSL Ozempic impact: Biotech giant says business shielded from big hitsThe biotech giant also outlined an inverse Uber-style surge fee to reward people donating blood outside peak hours.
출처: FinancialReview - 🏆 2. / 90 더 많은 것을 읽으십시오 »

Our biggest healthcare company says it isn’t scared of OzempicCSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
출처: theage - 🏆 8. / 77 더 많은 것을 읽으십시오 »